#Atai

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update AtaiBeckley (NASDAQ: ATAI) reported Q4 and full-year 2025 results and clinical updates on March 6, 2026. Key clinical milestones include a successful FDA End-of-Phase 2 meeting for BPL-003 and Phase 3 initiation targeted for Q2 2026, VLS-01 Phase 2 topline readout expected in H2 2026, and positive Phase 2a EMP-01 SAD results. Financially, cash and short-term securities totaled $220.7M at year-end and management expects runway into early 2029. The company completed a strategic combination and U.S. redomiciliation in late 2025.

1 week ago

#ATAI AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

www.stocktitan.net/news/ATAI/atai-beckley-r...

0 0 0 0

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression AtaiBeckley (NASDAQ: ATAI) announced a successful End-of-Phase 2 meeting with the FDA for BPL-003, its intranasal mebufotenin benzoate for treatment-resistant depression. The FDA indicated support for a dual pivotal Phase 3 program and provided feedback on the safety database.The company expects Phase 3 initiation on track for Q2 2026, notes BPL-003 has Breakthrough Therapy designation (Oct 2025), and will host a Virtual Investor Day on March 6, 2026 to detail the Phase 3 strategy.

1 week ago

#ATAI AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

www.stocktitan.net/news/ATAI/atai-beckley-a...

0 0 0 0

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder AtaiBeckley (NASDAQ: ATAI) reported positive topline results from a Phase 2a trial of EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder on February 26, 2026. The study met its primary safety objective with no serious adverse events and high retention.EMP-01 showed a placebo-adjusted LSAS reduction of 11.85 points at Day 43 (Hedges’ g=0.45; p=0.036 one-tailed), 49% CGI‑I responders vs. 15% placebo (NNT 2.95). Seventy-one patients enrolled across seven UK sites; detailed analyses will appear at scientific venues.

2 weeks ago

#ATAI AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

www.stocktitan.net/news/ATAI/atai-beckley-a...

0 0 0 0

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation AtaiBeckley (NASDAQ: ATAI) presented new clinical and preclinical data at the 64th Annual ACNP Meeting (Jan 12–15, 2026) in Nassau, Bahamas. A Phase 2b double-blind study of intranasal BPL-003 (mebufotenin benzoate) showed that a single 8 mg or 12 mg dose produced a significant, rapid, and sustained antidepressant effect versus a 0.3 mg sub-perceptual control at all timepoints, with both active doses reported as well-tolerated. The BPL-003 poster was selected for the Hot Topics Session. A separate preclinical poster on 5-MeO-DMT reported pharmacology, pharmacokinetics, and potential neuroplasticity-relevant effects supporting further investigation. The company said these results support moving toward Phase 3 evaluation for BPL-003.

1 month ago

#ATAI AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

www.stocktitan.net/news/ATAI/atai-beckley-p...

0 0 0 0

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference AtaiBeckley (NASDAQ: ATAI) provided a 2026 outlook ahead of the J.P. Morgan Healthcare Conference and highlighted clinical progress, corporate changes, and upcoming milestones.Key clinical updates: positive Phase 2b topline results for BPL-003 (mebufotenin benzoate) in TRD with single-dose durable effects; OLE data supporting a 12 mg repeat dose; Phase 3 guidance expected in Q1’26 with potential initiation in Q2’26 pending an FDA End-of-Phase 2 meeting. Additional 2026 catalysts include H2’26 topline readout for VLS-01 and Q1’26 topline data for EMP-01. Corporate: redomiciled to the U.S., added to the NASDAQ biotech index, and expects funding into 2029.

2 months ago

#ATAI AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

www.stocktitan.net/news/ATAI/atai-beckley-p...

0 0 0 0

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today

2 months ago

#ATAI AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

www.stocktitan.net/news/ATAI/atai-beckley-a...

0 0 0 0

3 months ago

#ATAI AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

www.stocktitan.net/news/ATAI/atai-beckley-a...

0 0 0 0

4 months ago

#ATAI AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/ATAI/atai-beckley-r...

0 0 0 0

4 months ago

Atai Life Sciences and Beckley Psytech have received FDA Breakthrough Therapy designation for their nasal spray BPL-003 (mebufotenin benzoate), targeting treatment-resistant depression in adults

#ATAI #ATAIStock #ATAINews #ATAIStockNews #ataiLifeSciences #ataiLifeSciencesLifeSciencesStock
$ATAI

0 0 0 0

atai Life Sciences Announces Pricing of Public Offering of Common Shares atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of

4 months ago

#ATAI atai Life Sciences Announces Pricing of Public Offering of Common Shares

www.stocktitan.net/news/ATAI/atai-life-scie...

0 0 0 0

atai Life Sciences Announces Proposed Public Offering of Common Shares atai Life Sciences (NASDAQ: ATAI) announced on October 16, 2025 the commencement of a proposed registered underwritten offering of its common shares.The company said it expects to grant underwriters a 30-day option to purchase additional common shares and that all shares will be sold by atai. The offering is subject to market and other conditions and may not be completed.atai intends to use net proceeds, together with existing cash and short-term investments, to advance clinical development, and for working capital and general corporate purposes. Jefferies is lead bookrunner.

4 months ago

#ATAI atai Life Sciences Announces Proposed Public Offering of Common Shares

www.stocktitan.net/news/ATAI/atai-life-scie...

0 0 0 0

5 months ago

atai Life Sciences shares rose nearly 15% on Tuesday after mid-stage trial results showed that its two-dose nasal spray treatment, BPL-003, led to rapid, significant, and long-lasting improvements in depression symptoms, with benefits lasting up to three months.

#ATAI #ATAIStock #AtaiLifeSciences

0 0 0 0

Most Searched, Tuesday September 23, 2025 – Crystal Equity Research

5 months ago

Most searched small-cap stocks, Tue Sept 23rd - #UAMY #RXRX #GLTO #ONDS #SLE #SLNH #LAES #PLUG #WRD #WLDN #VLRS #SEI #ATAI #MGNX #LUNR #LAC #ESPR #CERS #HOLO #AESI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Monday August 25, 2025 – Crystal Equity Research

6 months ago

Most searched small-cap stocks, Mon Aug 25th - #STSS #CGTX #CIFR #ATAI #VRNT #ETHZ #HIVE #ONDS #BBAI #RR #HCWB #ASST #THM #THAR #MGNI #LIDR #INHD #CBRL #ASM #AEHR - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates atai Life Sciences (NASDAQ: ATAI) reported Q2 2025 financial results and corporate updates, highlighting its planned strategic combination with Beckley Psytech. The company announced positive Phase 2b results for BPL-003 (intranasal mebufotenin benzoate) in treatment-resistant depression, meeting primary and secondary endpoints with a single dose showing effects for up to 8 weeks.Financial position shows $95.9 million in cash and equivalents as of June 30, 2025, with funding expected into second half of 2027. Q2 2025 saw R&D expenses of $11.1 million (down from $12.6M YoY) and net loss of $27.7 million (improved from $57.3M YoY). The company raised nearly $140 million in 2025 through fundraising efforts.Pipeline updates include delayed VLS-01 Phase 2 trial data now expected in H2 2026, ongoing EMP-01 Phase 2 study for social anxiety disorder, and development of novel 5-HT2A receptor agonists.

7 months ago

#ATAI atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/ATAI/atai-life-scie...

0 0 0 0

7 months ago

Psychedelic drug stocks surged after Bloomberg News reported AbbVie is in talks to acquire Gilgamesh Pharmaceuticals in a ~$1B deal.

#ATAI #CMPS #MNMD #ATAIStock #CMPSStock #MNMDStock #Psychedelic #PsychedelicDrugs #PsychedelicStocks #PsychedelicMedicines
$ATAI $CMPS $MNMD $ABBV

0 0 0 0

7 months ago

Atai Life Sciences shares dropped over 15% in after-hours trading after its portfolio company Recognify Life Sciences reported that its schizophrenia drug inidascamine failed to meet the primary endpoint in a Phase 2b trial.

#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences
$ATAI

0 0 0 0

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia Recognify Life Sciences, a subsidiary of atai Life Sciences (NASDAQ:ATAI), announced that its Phase 2b clinical trial for inidascamine in treating cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint of statistical significance. The study, involving 242 patients across the US and Europe, showed modest numerical improvements in cognitive and functional measures.Despite not achieving statistical significance, inidascamine demonstrated consistent improvement across multiple cognitive domains and maintained a favorable safety profile with no sedation, weight gain, or extrapyramidal symptoms. The company will continue analyzing secondary endpoints and subgroup data to identify potential responder populations and guide future development.

7 months ago

#ATAI Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

www.stocktitan.net/news/ATAI/recognify-life...

0 0 0 0

8 months ago

Atai Life Sciences shares rose after its psychedelic drug BPL-003, developed with Beckley Psytech, showed statistically significant reductions in depressive symptoms in a mid-stage trial for treatment-resistant depression (TRD).

#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Most searched small-cap stocks, Tue Jul 1st - #WETO #ATAI #YYAS #VVOS #VLRS #RUN #RXRX #PL #MNDJF #MDAI #LEU #EOSE #CYN #APLD #BTCS #AEVA #BMNR #ACHC #BGLC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0